A common hypothesis is that prostate cancer bone metastases first need to activate osteoclastic bone resorption, to then increase bone formation, which supports the clinical observation that Zoledronic acid, a bisphosphonate drug, and Denosumab, an anti-RANKL monoclonal antibody, are efficacious in the management of SREs of prostate cancer bone metastases and associated pain [46,47]. Here, TNFSF11 is linked to prostate cancer.